Quanterix CORP Form 4 insider transactions

Quanterix Corp. Director Scott Mendel increased his beneficial ownership of company shares and options on July 8, 2025, as part of the acquisition of Akoya Biosciences, Inc.

Quanterix Corp. Director Sarah E. Hlavinka acquired 2,615 shares of common stock on July 1, 2025, as compensation for her board service, increasing her total beneficial ownership to 60,070 shares.

Paul M. Meister, a Director at Quanterix Corp, acquired 2,242 shares of common stock valued at $6.69 per share on July 1, 2025, as compensation for board service.

Quanterix Corporation Director William P. Donnelly acquired 4,204 shares of common stock on July 1, 2025, as compensation for board service, increasing his total beneficial ownership to 143,298 shares.

Quanterix Corp Director David R. Walt acquired 2,148 shares of common stock on July 1, 2025, as compensation for board service, increasing his total beneficial ownership to 1,869,081 shares.

Masoud Toloue, President and CEO of Quanterix Corp, reported a future transaction involving the withholding of 254 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Quanterix Corporation's President and CEO, Masoud Toloue, reported the withholding of 1,242 shares of common stock to cover tax obligations related to the vesting of 3,722 restricted stock units.

Quanterix Corporation's Chief Financial Officer, Vandana Sriram, reported the disposition of 229 common shares on June 15, 2025, to cover tax obligations related to the vesting of 777 restricted stock units.

Quanterix Corp Director David R. Walt has substantially increased his beneficial ownership in the company by acquiring 160,000 shares of common stock in mid-June 2025.

Quanterix Corp's President and CEO, Masoud Toloue, has acquired 45,900 shares of common stock, signaling strong insider confidence in the company.

David R. Walt, a Director at Quanterix Corp (QTRX), has significantly increased his beneficial ownership in the company through two open market purchases totaling 210,000 shares in early June 2025.

William P. Donnelly, a Director at Quanterix Corp., has acquired 93,113 shares of common stock for approximately $506,400, increasing his beneficial ownership to 139,094 shares.

Quanterix Corporation's President and CEO, Masoud Toloue, reported a future transaction involving the withholding of 254 common shares to cover tax obligations related to the vesting of 761 restricted stock units, effective May 31, 2025.

Vandana Sriram, CFO of Quanterix Corp, disposed of 229 shares of common stock on May 15, 2025, to cover tax obligations upon the vesting of restricted stock units.

Masoud Toloue, President & CEO of Quanterix Corp, disposed of 1,242 shares of common stock on May 15, 2025, to cover tax obligations upon the vesting of restricted stock units.

Quanterix reported a 5% decrease in revenue for Q1 2025 and is implementing cost reduction initiatives to achieve $30 million in annual savings.

Masoud Toloue, President and CEO of Quanterix Corp, disposed of 254 shares of common stock to cover tax obligations arising from the vesting of restricted stock units.

Quanterix and Akoya Biosciences have amended their merger agreement, reducing the number of Quanterix shares to be issued and increasing the cash consideration for Akoya shareholders.

Vandana Sriram, CFO of Quanterix Corp, disposed of 229 shares of common stock on April 15, 2025, to cover tax obligations upon the vesting of restricted stock units.

Masoud Toloue, President and CEO of Quanterix Corp, reports the withholding of shares to cover tax obligations upon the vesting of restricted stock units.

Quanterix Corporation has entered into a securities purchase agreement with Akoya Biosciences, Inc., providing up to $30 million in convertible promissory notes to support Akoya's working capital needs pending a potential merger.

Director Paul M. Meister acquired 2,479 shares of Quanterix Corp common stock on April 1, 2025, in lieu of cash fees for board service.

Director David R. Walt acquired 2,156 shares of Quanterix Corp common stock on April 1, 2025, in lieu of cash fees for board service.

Director Sarah E. Hlavinka reports acquisition of 2,625 shares of Quanterix Corp common stock on April 1, 2025, through stock grants in lieu of cash fees.

Director William P. Donnelly acquired 2,681 shares of Quanterix Corp common stock on April 1, 2025, as compensation for board service.

Masoud Toloue, President and CEO of Quanterix Corp, disposed of 254 shares of common stock on March 31, 2025, to cover tax obligations upon the vesting of restricted stock units.

Quanterix Corp CEO Masoud Toloue disposed of 1,242 shares of common stock on March 15, 2025, to cover tax obligations arising from the vesting of restricted stock units.

Vandana Sriram, CFO of Quanterix Corp, reports the withholding of shares to cover tax obligations upon the vesting of restricted stock units.

Quanterix's CEO addresses investor concerns regarding the proposed acquisition of Akoya Biosciences, emphasizing long-term value creation and recurring revenue opportunities despite market headwinds.

Quanterix reports an 11% revenue increase for Q4 2024 and highlights the pending acquisition of Akoya Biosciences.